Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer

References

• Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389:847–860.
   PubMed Web of Science ®Google Scholar
• Be M. Psychosocial correlates of breast cancer and its treatments. Psychol Bull. 1980;87:108–131.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of her2- overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726.
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36.
   PubMed Web of Science ®Google Scholar
• Pérez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366–3373.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. New England J Med. 2011;365(14):1273–1283.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab,as adjuvant treatments of breast cancer: final results of theFinHer Trial. J Clin Oncol. 2009;27:5685–5692.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review. 2014: p. 1975–2011. https://seer.cancer.gov/
   Google Scholar
• Taylor D. The reality of economics for oncologists. Breast. 2017;33:183–190.
   PubMed Web of Science ®Google Scholar
• Hanly P, Timmons A, Walsh PM. Linda sharp, breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value in Health. 2012 May;15(3):429–436.
   PubMed Web of Science ®Google Scholar
• Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol. 2011;77:109–130.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
   PubMed Web of Science ®Google Scholar
• Aboutorabi A, Hadian M, Ghaderi H, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer global. J Health Sci. 2015;7(1): 98-106.
   Google Scholar
• Amir Ansaripour CA, Uyl-de Groot W. Ken Redekop adjuvant trastuzumab therapy for early her2-positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. PharmacoEconomics. 2018;36:91–103.
   PubMed Web of Science ®Google Scholar
• Buendía JA, Vallejos C, Pichón-Rivière A. Cost-effectiveness of trastuzumab in Colombia ARTÍCULO ORIGINAL. Biomédica 2013;33:411–417.
   Google Scholar
• Chen W, Jiang Z, Shao Z, et al. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value in Health. 2009;12(3): S82-S84.
   Google Scholar
• Dedes KJ, Szucs TD, Imesch P, et al. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial . Ann Oncol. 2007;18:1493–1499.
   PubMed Web of Science ®Google Scholar
• Neyt M, Huybrechts M, Hulstaert F, et al. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy. 2008;87:146–159.
   PubMed Web of Science ®Google Scholar
• Hall PS, Hulme C, McCabe C, et al. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. Pharmacoeconomics. 2011 May; 29(5):415–432. .
   PubMed Web of Science ®Google Scholar
• Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25:625–633.
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007 Aug 1; 110(3):489–498.
   PubMed Web of Science ®Google Scholar
• Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu–positive breast. Cancer J Clin Oncol. 2007;25:634–641 .
   PubMed Web of Science ®Google Scholar
• Lang H-C, Chen H-W, Chiou T-J, et al. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neupositive early breast cancer in Taiwan. J Med Econ. 2016;19(10):923–927.
   PubMed Web of Science ®Google Scholar
• Leung W, Kvizhinadze G, Nair N, et al. Adjuvant Trastuzumab in HER2-positive early breast cancer by age and hormone receptor status: a cost-utility analysis. PLoS Med. 2016;13(8):e1002067. .
   PubMed Web of Science ®Google Scholar
• J A M, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. PharmacoEconomics. 2007;25(5):429–442.
   PubMed Web of Science ®Google Scholar
• Purmonen TT, Emma Pänkäläinen JH, Turunen O, et al. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer trial. Acta Oncol. 2011;50(3):344–352. .
   PubMed Web of Science ®Google Scholar
• Seferina SC, Ramaekers BLT, de Boer M, et al. Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: a study of the Southeast Netherlands. Breast Cancer Consortium Oncotarget. 2017;8(No. 45):79223–79233.
   Google Scholar
• Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109:559–566.
   PubMed Web of Science ®Google Scholar
• Chris Skedgel MDE, Daniel Rayson MD, Younis T. The cost-utility of sequential adjuvant Trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA trial. Value in Health. 2009;12(5):641–648.
   PubMed Web of Science ®Google Scholar
• Chan ALF, Leung HW, Lu CL, et al. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother. 2009;43:296–303.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–1205.
   PubMed Web of Science ®Google Scholar
• Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al. Challenges to eff ective cancer control in China, India, and Russia. Lancet Oncol. 2014;15:489–538.
   PubMed Web of Science ®Google Scholar
• Senkus E, Kyriakides S, Ohno S, et al. on behalf of the ESMO Guidelines committee primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Supplement5):v8–v30.
   PubMed Web of Science ®Google Scholar
• Mustacchi G, Puglisi F, Am M, et al. Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients. Future Oncol. 2015;11(10):1493–1500.
   PubMed Web of Science ®Google Scholar